

















GXH Half Year Result - Financial Overview



15% increase vs FY22



Operating Profit/EBIT \$24.7m

21% increase vs FY22



Net Profit After Tax \$11.4m

18% increase vs FY22 (attributable to shareholders)









\$11.6m

13% decrease vs FY22





the doctors + House Call

\$9.3m

63% increase vs FY22









\$6.6m


166% increase vs FY22







Operational Highlights



- > \$45m increase in Group Revenue year-onyear
- ➤ 18% increase in Net Earnings Attributable to Shareholders versus last year
- Rollout of new Unichem and Life Pharmacy App - MedAdvisor
- HouseCall virtual care continues to expand services
- GXH recognised as a Top 10 most desirable place to work in New Zealand by Randstad



















Pharmacy Division

New Zealand's largest network of health retailers: supporting easy access to quality health care











Pharmacy Performance





Revenue up 6% to \$179.7m



Operating Profit down 13% to \$11.6m due to reduction in COVID-19 vaccination activity




The increase in **Pharmacy Revenue** was primarily due to growth in dispensary activity




Total script volumes up 15%

Pharmacy Operating Revenue (\$m)



Pharmacy Operating Profit (\$m)





Operational Highlights - Pharmacy



- ✓ Influenza vaccination volumes up 92%
- Investment in new Living Rewards platform
- ✓ Partnership with technology company MedAdvisor
- √ 1.9m loyalty members

Living Rewards Members Spend More




more than non-members



48%

more than non-members





1,916,504 Living **Rewards members**



Pharmacy Will Win By Focusing on the Customer





Pharmacy Strategy



Brand & customer

Differentiated brand and products, recognising customer loyalty



Retail disciplines

Professional instore experience, margin management



Omni-channel experience

Care & advice accessible to the customer in multiple channels



Network scale & leadership

Leveraging our trusted brands, advocating for equity for all New Zealanders



Cost focus

Workforce productivity & occupancy cost control



Medical Division

Growth, leadership and sustainable models of care









Medical Performance







Revenue up 48% to \$68.2m, driven by COVID-19 testing, vaccinations, COVID-19 care in the community and acquisitions




Operating Profit up 63% to \$9.3m, driven by COVID-19 activity, procurement efficiencies, cost management and acquisitions




345,000 enrolled patients as at 30 September 2022, an increase of 57,000 (+20%) since 30 September 2021

Medical Operating Revenue (\$m)



Medical Operating Profit (\$m)







Operational Highlights - Medical

- ✓ Successful completion of four acquisitions, to close with 57 medical centres
- ✓ Strong pipeline of future acquisitions
- ✓ Continued development of the HouseCall virtual care service offering
- ✓ The Doctors has New Zealand's largest general practice enrolled patient base




345,000 enrolled patients

Acquisitions



Enrolled Patients ('000)





Medical Focused on Organic Growth and Acquisitions

the doctors + House Call

Medical Strategy		
	Patient & brand	High quality patient care
	Scale	Targeted centre acquisitions
	Technology	Utilising data and systems, omni-channel offering
	Operational improvement	Continuous improvement focus, clinical development
ute	Cost and margin focus	Workforce productivity & margin management



Community Health Division

Delivering sustainable services to maintain and support clients' independence within their own home









Community Health Performance







Revenue up 14% to \$107.2m



Operating Profit increased 166% to \$6.6m



Improved performance reflects strategy of supporting clients with higher clinical needs and improving profitability of contracts




Cost efficiencies have resulted from investment in people, technology and systems




Continued advocacy for additional funding to support sector sustainability

Community Health Operating Revenue (\$m)



Community Health Operating Profit (\$m)








Operational Highlights - Community





- ✓ Operating margin of 6% (up from 3%)
- Improvements in labour efficiency as a result of investment in systems
- ✓ Access Virtual Assistant (AVA) support worker digital app well-entrenched
- ✓ Focus on higher and complex support needs
- Continued advocacy for nurse pay parity
- ✓ Working alongside Kaupapa Māori providers to support equity of access







Community Health Targeting Profitable Growth





Community Health Strategy



Client

Higher clinical needs & excellent client experience



Technology

Digital and systems development



Sector representation Advocating for sustainable funding and equity for all clients



Cost and margin

Workforce productivity & contract margin management



Group Financial Result

6 months ending 30 September 2022




Group Revenue and Operating Profit

GXH Operating Revenue (\$m)



- Revenue of \$355.1m, up 15%
- Increased revenue performance in all three divisions

GXH Operating Profit (\$m)



- Operating Profit of \$24.7m, up 21% versus prior period
- Operating profit growth of 54% over three years
- Growth supported by COVID-19 activity and acquisitions

Group NPAT, EPS and Dividend

GXH Net Profit after Tax Attributable to Shareholders (\$m)



GXH Net Profit after Tax Attributable to Shareholders (cps)



Dividend / EPS

- NPAT attributable to shareholders of \$11.4m, up 18%
- EPS at 7.9 cps, an increase of 17% on the prior year
- EPS growth of 62% over last three years
- Interim dividend of 3.5cps declared payment date of 16 December 2022




Working Capital and Operating Cash Flow

Gearing Ratio (debt / debt + equity)



- Gearing ratio of 12% in FY22
- Undrawn debt facilities of \$44m as at 30 September 2022
- Net cash position of \$18.9m as at 30 September 2022 (up \$13.0m on prior period)
- Continued working capital management has positioned GXH well to take advantage of future investment opportunities
- Financing ratios (pre IFRS16):
 - Debt / EBITDA 0.4x
 - Operating Profit / Interest 38.4x

GXH Operating Cash Flow (\$m)



Operating Cash Flow of \$28.9m

Enabling investment (\$7.1m) in:

- Four medical centre acquisitions
- Three shareholding increases medical (2), pharmacy (1)
- Ongoing site capex requirements
- Loyalty, MedAdvisor and other digital capability



- > Challenging labour market, with workforce shortages and inflationary pressure
- Focus remains on growth through acquisitions, operating model refinement and investment in service offerings
- COVID-19 related earnings expected to reduce over the remainder of the financial year, with return to Group pre COVID-19 profitability levels (adjusted for acquisitions)
- > Dividend of 3.5cps declared for the half-year ended 30 September 2022



About Green Cross Health





Our Purpose

Working together to support healthier communities.

We are passionately committed to the health and wellness of New Zealand, and to providing the best support, care and advice to our communities.

This is our promise.


















Who We Are



Pharmacies providing extensive range of health, wellness and beauty related products and services across communities throughout New Zealand, supported by digital offerings



General practice networks across New Zealand, offering in-practice and virtual services



Personal care, nursing, rehabilitation and household assistance delivered within homes across New Zealand

As at 30 Sept 2022



The information in this presentation was prepared by Green Cross Health Limited (GXH) with due care and attention. However, the information is supplied in summary form and is therefore not necessarily complete, and no representation is made as to the accuracy, completeness or reliability of the information. In addition, neither GXH nor any of its subsidiaries, directors, employees, shareholders nor any other person shall have liability whatsoever to any person for any loss (including, without limitation, arising from any fault or negligence) arising from this presentation or any information supplied in connection with it.

This presentation may contain forward-looking statements and projections. These reflect GXH current expectations, based on what it thinks are reasonable assumptions. GXH gives no warranty or representation as to its future financial performance or any future matter. Except as required by law or NZX listing rules, GXH is not obliged to update this presentation after its release, even if things change materially. This presentation does not constitute financial advice. Further, this presentation is not and should not be construed as an offer to sell or a solicitation of an offer to buy GXH securities and may not be relied upon in connection with any purchase of GXH securities.

This presentation contains a number of non-GAAP financial measures, including Operating Revenue and Operating Profit. As they are not defined by GAAP or IFRS, GXH calculation of these measures may differ from similarly titled measures presented by other companies and they should not be considered in isolation from, or construed as an alternative to, other financial measures determined in accordance with GAAP. Although GXH believes they provide useful information in measuring the financial performance and condition of GXH business, readers are cautioned not to place undue reliance on these non-GAAP financial measures.

The information contained in this presentation should be considered in conjunction with the consolidated interim financial statements for the period ended 30 September 2022.















